SUT BEZI SARATONI KASALLIGINI KIMYOTERAPIYA BILAN DAVOLASHNING YUTUQ VA KAMCHILIKLARI
Keywords:
sut bezi saratoni, kimyoterapiya, doksorubitsin, paklitaksel, neoadjuvant terapiya, toksiklik, umumiy omon qolish.Abstract
Sut bezi saratoni (SBS) ayollar orasida eng ko‘p uchraydigan onkologik kasallik bo‘lib, global o‘lim sabablaridan biri hisoblanadi. Kimyoterapiya kasallikning erta va rivojlangan bosqichlarida muhim davolash usuli sifatida qo‘llaniladi. Ayniqsa, antrasiklinlar, taksanlar va platina asosidagi preparatlar adjuvant, neoadjuvant hamda metastatik bosqichlarda samarali hisoblanadi. Ushbu maqolada kimyoterapiyaning klinik samaradorligi, omon qolish ko‘rsatkichlariga ta’siri hamda nojo‘ya ta’sirlari tahlil qilinadi.
References
1. World Health Organization. Breast cancer fact sheet. 2023.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer. Lancet. 2012.
3. The New England Journal of Medicine. Anthracycline and taxane-based chemotherapy in early breast cancer. 2018.
4. Journal of Clinical Oncology. Adjuvant chemotherapy for breast cancer: long-term outcomes. 2019.
5. National Comprehensive Cancer Network (NCCN). Breast Cancer Clinical Practice Guidelines. 2024
